{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T19:45:03Z","timestamp":1788637503885,"version":"build-2803163510"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods & Clinical Development"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.omtm.2022.12.002","type":"journal-article","created":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T02:09:56Z","timestamp":1670378996000},"page":"90-98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Dasatinib is a potent enhancer for CAR T\u00a0cell generation by CD3-targeted lentiviral vectors"],"prefix":"10.1016","volume":"28","author":[{"given":"Angela H.","family":"Braun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika M.","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naphang","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian J.","family":"Buchholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2022.12.002_bib1","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41434-021-00246-w","article-title":"Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany","volume":"28","author":"Albinger","year":"2021","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2022.12.002_bib2","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.medj.2022.05.001","article-title":"Understanding CAR T\u00a0cell-tumor interactions: paving the way for successful clinical outcomes","volume":"3","author":"Korell","year":"2022","journal-title":"Med"},{"key":"10.1016\/j.omtm.2022.12.002_bib3","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1159\/000525052","article-title":"Treatment with living drugs: pharmaceutical aspects of CAR T\u00a0cells","volume":"107","author":"Holzinger","year":"2022","journal-title":"Pharmacology"},{"key":"10.1016\/j.omtm.2022.12.002_bib4","doi-asserted-by":"crossref","first-page":"876339","DOI":"10.3389\/fimmu.2022.876339","article-title":"Impact of manufacturing procedures on CAR T\u00a0cell functionality","volume":"13","author":"Watanabe","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2022.12.002_bib5","doi-asserted-by":"crossref","first-page":"16015","DOI":"10.1038\/mto.2016.15","article-title":"Clinical manufacturing of CAR T\u00a0cells: foundation of a promising therapy","volume":"3","author":"Wang","year":"2016","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omtm.2022.12.002_bib6","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","article-title":"Global manufacturing of CAR T\u00a0cell therapy","volume":"4","author":"Levine","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2022.12.002_bib7","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2326-6066.CIR-17-0405","article-title":"Reducing ex\u00a0vivo culture improves the antileukemic activity of chimeric antigen receptor (CAR) T\u00a0cells","volume":"6","author":"Ghassemi","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omtm.2022.12.002_bib8","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T\u00a0cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2022.12.002_bib9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.omtm.2018.10.006","article-title":"Surface-engineered lentiviral vectors for selective gene transfer into subtypes of lymphocytes","volume":"12","author":"Frank","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2022.12.002_bib10","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1038\/mt.2008.128","article-title":"Targeted cell entry of lentiviral vectors","volume":"16","author":"Funke","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2022.12.002_bib11","doi-asserted-by":"crossref","first-page":"e1005641","DOI":"10.1371\/journal.ppat.1005641","article-title":"Receptor-targeted Nipah virus glycoproteins improve cell-type selective gene delivery and reveal a preference for membrane-proximal cell attachment","volume":"12","author":"Bender","year":"2016","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.omtm.2022.12.002_bib12","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.1182\/blood-2012-02-412973","article-title":"T-cell receptor gene transfer exclusively to human CD8(+) cells enhances tumor cell killing","volume":"120","author":"Zhou","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2022.12.002_bib13","doi-asserted-by":"crossref","first-page":"e9158","DOI":"10.15252\/emmm.201809158","article-title":"In\u00a0vivo generation of human CD19-CAR T\u00a0cells results in B-cell depletion and signs of cytokine release syndrome","volume":"10","author":"Pfeiffer","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.omtm.2022.12.002_bib14","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1089\/hum.2019.248","article-title":"CD8-specific DARPins improve selective gene delivery into human and primate T lymphocytes","volume":"31","author":"Frank","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2022.12.002_bib15","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.omtm.2021.09.019","article-title":"Monitoring CAR T\u00a0cell generation with a CD8-targeted lentiviral vector by single-cell transcriptomics","volume":"23","author":"Charitidis","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2022.12.002_bib16","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.4049\/jimmunol.1500956","article-title":"Exclusive transduction of human CD4+ T\u00a0cells upon Systemic delivery of CD4-targeted lentiviral vectors","volume":"195","author":"Zhou","year":"2015","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omtm.2022.12.002_bib17","first-page":"30239","article-title":"In\u00a0vivo generation of CAR T\u00a0cells selectively in human CD4+ lymphocytes","volume":"20","author":"Agarwal","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2022.12.002_bib18","first-page":"5702","article-title":"Combining T-cell-specific activation and in\u00a0vivo gene delivery through CD3-targeted lentiviral vectors","volume":"4","author":"Frank","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.omtm.2022.12.002_bib19","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2217\/fvl.09.72","article-title":"Internalization and fusion mechanism of vesicular stomatitis virus and related rhabdoviruses","volume":"5","author":"Sun","year":"2010","journal-title":"Future Virol."},{"key":"10.1016\/j.omtm.2022.12.002_bib20","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.omtm.2019.03.003","article-title":"Highly efficient and selective CAR-gene transfer using CD4- and CD8-targeted lentiviral vectors","volume":"13","author":"Jamali","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2022.12.002_bib21","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/0042-6822(69)90154-8","article-title":"Enhancement and inhibition of avian sarcoma viruses by polycations and polyanions","volume":"38","author":"Toyoshima","year":"1969","journal-title":"Virology"},{"key":"10.1016\/j.omtm.2022.12.002_bib22","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/jgm.2653","article-title":"Poloxamer synperonic F108 improves cellular transduction with lentiviral vectors. Achtung, funktioniert bei mir nicht (Tobi)","volume":"14","author":"H\u00f6fig","year":"2012","journal-title":"J.\u00a0Gene Med."},{"key":"10.1016\/j.omtm.2022.12.002_bib23","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1182\/blood-2007-04-084814","article-title":"Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation","volume":"111","author":"Schade","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2022.12.002_bib24","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1002\/cncr.32627","article-title":"Long-term results of frontline dasatinib in chronic myeloid leukemia","volume":"126","author":"Maiti","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.omtm.2022.12.002_bib25","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","article-title":"The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants","volume":"66","author":"Tokarski","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.omtm.2022.12.002_bib26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jim.2008.09.014","article-title":"Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers","volume":"340","author":"Lissina","year":"2009","journal-title":"J.\u00a0Immunol. Methods"},{"key":"10.1016\/j.omtm.2022.12.002_bib27","doi-asserted-by":"crossref","first-page":"eaau5907","DOI":"10.1126\/scitranslmed.aau5907","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T\u00a0cells","volume":"11","author":"Mestermann","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2022.12.002_bib28","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.3389\/fmicb.2018.03228","article-title":"IFITM genes, variants, and their roles in the control and pathogenesis of viral infections","volume":"9","author":"Zhao","year":"2018","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.omtm.2022.12.002_bib29","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1089\/hum.2015.156","article-title":"Human, pig, and mouse interferon-induced transmembrane proteins partially restrict pseudotyped lentiviral vectors","volume":"27","author":"Hornick","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2022.12.002_bib30","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41408-022-00694-6","article-title":"Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study","volume":"12","author":"Yang","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.omtm.2022.12.002_bib31","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41408-022-00688-4","article-title":"Novel CD19 chimeric antigen receptor T\u00a0cells manufactured next-day for acute lymphoblastic leukemia","volume":"12","author":"Zhang","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.omtm.2022.12.002_bib32","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41551-021-00842-6","article-title":"Rapid manufacturing of non-activated potent CAR T\u00a0cells","volume":"6","author":"Ghassemi","year":"2022","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.omtm.2022.12.002_bib33","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1182\/bloodadvances.2018028720","article-title":"Pharmacologic control of CAR-T cell function using dasatinib","volume":"3","author":"Weber","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.omtm.2022.12.002_bib34","series-title":"Transient Rest Restores Functionality in Exhausted CAR-T Cells through Epigenetic Remodeling","first-page":"372","author":"Weber","year":"2021"},{"key":"10.1016\/j.omtm.2022.12.002_bib35","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41467-022-28243-6","article-title":"CAR T\u00a0cells redirected to cell surface GRP78 display robust anti-acute myeloid leukemia activity and do not target hematopoietic progenitor cells","volume":"13","author":"Hebbar","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtm.2022.12.002_bib36","series-title":"Genetic in\u00a0Vivo Engineering of Human T Lymphocytes in Mouse Models","author":"Weidner","year":"2020"}],"container-title":["Molecular Therapy - Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050122001759?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050122001759?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:29:15Z","timestamp":1762421355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050122001759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":36,"alternative-id":["S2329050122001759"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2022.12.002","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dasatinib is a potent enhancer for CAR T\u00a0cell generation by CD3-targeted lentiviral vectors","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2022.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors.","name":"copyright","label":"Copyright"}]}}